When was Feldan founded?

Feldan was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Where is Feldan located?

Feldan is headquartered in Quebec City, Canada. It is registered at 2577 De Miniac, St-Laurent.

Who is the current CEO of Feldan?

Francois Thomas Michaud of Feldan.

How many employees does Feldan have?

As of Sep 30, 2026, the latest employee count at Feldan is 48.

Is Feldan a funded company?

Feldan is a funded company, having raised a total of $52.9M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 30, 2009.

When was the latest funding round of Feldan?

Feldan's latest funding was a $***** Series B round on Apr 16, 2025, with participation from 1 investor.

Where does Feldan rank among its competitors?

Feldan ranks 88th amongst 2103 active competitors, of which 469 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Feldan?

Feldan's top competitors include Antheia, Synthego and Genedit. Among them, Antheia secured the most recent funding round in January, 2026.

Feldan - 2026 Company Profile, Team, Funding & Competitors

Company Details

Feldan is developing regenerative medicine therapeutic applications based on Feldan’s proprietary technology. The company has developed Feldan Shuttle, a protein-based technology platform that directly delivers proteins – such as nucleases or transcription factors - inside cells to specific cellular compartments. The Shuttle can overcome obstacles faced by nucleic acid delivery for therapeutic use by decreasing the regulatory process and accelerating the translation of discoveries into clinical applications. The Shuttle also allows enables the development of in-house medical applications as well as in collaboration with partners.

Website: www.feldan.com/
Social
Email ID: *****@feldan.com
Phone Number: +1 **********
Registered Address: 2577 De Miniac, St-Laurent

Key Metrics

Founded Year

2007

Location

Quebec City, Canada

Stage

Series B

Total Funding

$52.9M in 9 rounds

Latest Funding Round

Series B, Apr 16, 2025, $*****

Investors

Fonds de solidarite FTQ & 13 more

Ranked

88^th among 2103 active competitors

Employee Count

48 as on Sep 30, 2026

Similar Companies

Antheia & 2828 more

View Feldan's full profile

Feldan is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Feldan Bio Inc. CIN: 677220-0 , Canada, Active	May 15, 2007	-	-	-

Feldan has raised a total funding of $52.9M over 9 rounds. Its first funding round was on Apr 30, 2009. Its latest funding round was a Series B round on Apr 16, 2025 for $*****. 1 investor participated in its latest round. Feldan has 14 institutional investors.

Here is the list of recent funding rounds of Feldan:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 16, 2025	3980628	Series B	5992991	7934433	6188334	8366547
Feb 18, 2025	2617301	Series B	9566309	6191805	2076844	Linearis
Sep 04, 2024	8653149	Series B	2228116	9578559	Genesys Capital & 1 more	9586603

Access funding benchmarks and valuations. Sign up today!

View details of Feldan's funding rounds and investors

Here are the details of Feldan's key team members:

Francois Thomas Michaud: CEO of Feldan.

Feldan's Board of Directors

Feldan's board has 7 active members. Paul F. Truex, Sandoval-little Elisabeth, James Stiff, François-thomas Michaud, Eric Gordon Carter, Nathalie Chauret and David J Mazzo are independent board members.

Here is the list of Feldan's board of directors:

Name	Type	Representing	Status	Duration
Paul F. Truex	Independent board member	-	Current	8y 1m
zkkykki	Independent board member	-	Current	3y 1m
iyrmuia	Independent board member	-	Current	5y 5m
{fdxhlm	Independent board member	-	Current	1y 2m
adlssgu	Independent board member	-	Current	8y 2m
zsbblqq	Independent board member	-	Current	9y 8m
ulhonmt	Independent board member	-	Current	7y 2m

View details of Feldan's Founder profiles and Board Members

Feldan's employee count trend

Feldan has 48 employees as of Sep 26. Here is Feldan's employee count trend over the years:

Uncover Feldan's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Feldan include Antheia, Synthego and Genedit. Here is the list of Top 10 competitors of Feldan, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	68/100
2nd	Synthego 2012, Redwood City (United States), Acquired	Manufacturer of custom CRISPR gene editors and molecular biology reagents	$460M	8VC, Perceptive Advisors & 31 others	67/100
3rd	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	66/100
4th	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 15 others	65/100
7th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
8th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, Norwest & 22 others	64/100
9th	enGene 1999, Saint laurent (Canada), Public	Developer of oral non-viral gene therapy platform	$54M	Hercules Capital, Lumira Ventures & 15 others	63/100
10th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Decheng Capital, Eclipse	63/100
88th	Feldan 2007, Quebec City (Canada), Series B	Developing delivery system of proteins inside cells directly	$52.9M	Cystic Fibrosis Foundation, Genesys Capital ... & 12 others	52/100